Although the reduction in proliferation did not seem to be dependent on the mutation status, it might still be interesting to test inhibitors that not “only” target pIGF1R but also IGF1R expression, especially in pIGF1R inhibition-resistant CD45+ MM [33,34]. The gene discussed is PTPRC; the disease is Miyoshi myopathy.